Share This Article:
FDA Issues Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids
12 Jul, 2012 WorkersCompensation.com
Washington, DC (WorkersCompensation.com) - The FDA has approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications.
ER/LA opioids are highly potent drugs that are approved to treat moderate to severe persistent pain for serious and chronic conditions (list of ER/LA opioid products). The misuse and abuse of these drugs have resulted in a serious public health crisis of addiction, overdose, and death.
The REMS is part of a multi-agency Federal effort to address the growing problem of prescription drug abuse and misuse. The REMS introduces new safety measures to reduce risks and improve safe use of ER/LA opioids while continuing to provide access to these medications for patients in pain.
Additional Information
- Questions and Answers: FDA approves a Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics
7/9/2012 - Blueprint for Prescriber Continuing Education (PDF - 104KB)
- FDA introduces new safety measures for extended-release and long-acting opioid medications
FDA news release (7/9/2012) - FDA Works to Reduce Risk of Opioid Pain Relievers
FDA Consumer Update - ER/LA Opioid Analgesics REMS (PDF - 912KB)
- Medication Guide Template for ER/LA Opioid Analgesics REMS (PDF - 47KB)
Read Also
- Sep 19, 2023
- WorkersCompensation.com
- Sep 18, 2023
- WorkersCompensation.com
- Sep 12, 2023
- WorkersCompensation.com
About The Author
About The Author
- WorkersCompensation.com
More by This Author
- May 11, 2023
- WorkersCompensation.com
- May 10, 2023
- WorkersCompensation.com
- Mar 30, 2023
- WorkersCompensation.com
Read More
- Sep 19, 2023
- WorkersCompensation.com
- Sep 18, 2023
- WorkersCompensation.com
- Sep 12, 2023
- WorkersCompensation.com
- Sep 08, 2023
- WorkersCompensation.com
- Sep 06, 2023
- WorkersCompensation.com
- Sep 05, 2023
- NCCI